Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). In this small trial involving 106 patients, a higher proportion of patients in the aflibercept …
Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth
Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical device market to grow from nearly $800 million in 2021 to $1.7 billion in 2026, at …
Eyeque Announces Series C Closing With More Than $57 Million in Capital Raised
EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-home vision tests using optical smartphone attachments that consumers can use to self-administer a refractive …
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMD
Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing agreement with DelSiTech, a provider of biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical …
Aequus, reVision to collaborate on Stargardt disease treatment
Aequus Pharmaceuticals and reVision Therapeutics will collaborate to develop a treatment for Stargardt disease, according to a press release.In addition, the agreement grants Aequus the option to acquire the North American commercial rights to REV-0100 from reVision.
Gene therapy start-up Vedere Bio II launches to treat blindness
The company, Vedere Bio II, launched with $77 million in series A financing to develop what it calls a “mutation agnostic optogenetics technology” to restore vision. As its name suggests, Vedere Bio II is a sequel to its predecessor company, Vedere Bio, which Novartis quietly acquired last year in a deal worth up to $280 million.
AI-based eye test could help prevent severe vision loss
Researchers from Imperial College London and University College London (UCL) carried out a clinical trial using retinal imaging technology known as Detection of Apoptosis in Retinal Cells (DARC). When tested on 113 patients in the trial, the technology was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes …
Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weeks
Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evaluated Beovu dosed every 4 weeks.1,3 Both trials demonstrated an overall well-tolerated safety profile.
Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DME
Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of three dose levels of THR-687 (0.4, 1.0 or 2.5mg) in subjects with center-involved DME following a single intravitreal …
Berlin’s Dopavision raises €12M to halt myopia progression in children and adolescents; here’s how
Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.Dopavision raises Series A roundIn a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure …
